GlaxoSmithKline opens pneumonia vaccine plant In Singapore

Drug maker GlaxoSmithKline (GSK) on Tuesday opened a $600 million plant in Singapore that is slated to begin producing vaccines to fight pneumonia-causing bacteria in 2011, Reuters reports.

According to Reuters, the "vaccine protects infants and children under age 2 from the bacterium streptococcus pneumoniae, which causes diseases like pneumonia, meningitis, bronchitis, acute sinusitis and inflammation of the inner layer of the heart or endocarditis." These diseases kill almost one million children annually, and 90 percent of the deaths occur in developing countries.

The pneumococcal conjugate vaccine was introduced in the U.S. in 2000, resulting in a "sharp drop in pneumococcal disease in children," Reuters reports. However, it is not yet available in many developing countries because the cost is prohibitive. GSK CEO Andrew Witty said the company's new price flexibility policy would make its vaccines and other treatments more affordable for people in developing countries.

Witty said it will take "a year or two" to make sure the "production processes [in the new plant] are running at the appropriate level of quality" (Wong-Anan, Reuters, 6/9).  According to the Straits Times, these processes include visits from international health authority auditor teams, including the FDA and the WHO (Khalik, Straits Times, 6/10).

GSK has a site in Belgium that also manufactures the vaccine (Reuters, 6/9).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals positive impact of repeat COVID-19 vaccinations